Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18379205 | 0.88 | KMT2A (0.41) | KMT2ASMN1; SMN2OPRL1KDM4EPOLB | |
| SCHEMBL4550376 | 0.88 | KMT2A (0.41) | KMT2ASMN1; SMN2OPRL1KDM4EPOLB | |
| SCHEMBL69424 | 0.87 | — | — | |
| SCHEMBL4550252 | 0.85 | SMN1; SMN2 (0.44) | KMT2ASMN1; SMN2ACHE | |
| Hydrochloric Acid SCHEMBL27859607 | 0.84 | SMN1; SMN2 (0.50) | KMT2ASMN1; SMN2KDM4ESPHK1MAPT | |
| SCHEMBL4550213 | 0.83 | SMN1; SMN2 (0.34) | KMT2ASMN1; SMN2OPRL1OPRD1OPRK1 | |
| SCHEMBL11919045 | 0.82 | KMT2A (0.56) | KMT2ASMN1; SMN2ACHE | |
| SCHEMBL11919058 | 0.82 | KMT2A (0.56) | KMT2ASMN1; SMN2OPRL1KDM4EACHE | |
| SCHEMBL17946979 | 0.81 | KMT2A (0.47) | KMT2ASMN1; SMN2OPRL1KDM4EPOLB | |
| SCHEMBL11919193 | 0.81 | KDM4E (0.50) | KMT2ASMN1; SMN2OPRL1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044334-A2 | METHODS AND COMPOSITIONS FOR MODULATING KRAS(G12D) | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2024-02-29 | — | — | WO | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | KMT2A 2280/4885SMN1; SMN2 2262/4885OPRL1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.